SEATTLE—Kyle Piskel, Chief Financial Officer of Adaptive Biotechnologies Corp (NASDAQ:ADPT), has reported a sale of company stock. According to a recent filing, Piskel sold 248 shares at a price of $4.98 each, totaling $1,235. Following this transaction, Piskel holds 154,330 shares directly.
The sale was conducted to cover tax withholding obligations related to the vesting of restricted stock units (RSUs). This transaction was part of the company's equity incentive plans, requiring a sell-to-cover action and was not a discretionary trade by Piskel.
In other recent news, Adaptive Biotechnologies Corp. has reported a 52% surge in Minimal Residual Disease (MRD) revenue, reaching $37.5 million, during its third-quarter 2024 earnings call. In addition to this, the company's total revenue saw a 22% increase, amounting to $46.4 million. Despite these promising figures, Adaptive Biotechnologies recorded a net loss of $32.1 million for the quarter. Other significant developments include a new Medicare gapfill rate for its clonoSEQ test and expanded Medicare coverage for mantle cell lymphoma. Furthermore, the company has updated its full-year guidance, projecting a rise in its MRD revenue and a reduction in operating expenses. Yet, it's worth noting that analysts highlighted the company's net loss and a 38% reduction in cash reserves compared to the previous year. Despite these challenges, Adaptive Biotechnologies remains committed to financial discipline while actively pursuing growth in MRD and Immune Medicine sectors.
InvestingPro Insights
While Kyle Piskel's recent stock sale was a routine transaction to cover tax obligations, it's worth examining Adaptive Biotechnologies Corp's (NASDAQ:ADPT) current financial position for a more comprehensive view.
According to InvestingPro data, Adaptive Biotechnologies has a market capitalization of $654.52 million. The company's revenue for the last twelve months as of Q3 2023 stood at $177.28 million, with a quarterly revenue growth of 22.46% in Q3 2023. This growth is particularly noteworthy given the company's overall revenue decline of 1.34% over the past year.
Despite the recent revenue growth, Adaptive Biotechnologies faces some financial challenges. An InvestingPro Tip indicates that the company is quickly burning through cash, which could be a concern for investors. Additionally, the company is not profitable over the last twelve months, with a negative gross profit margin of -2.75% and an operating income margin of -94.28%.
On a positive note, another InvestingPro Tip suggests that Adaptive Biotechnologies' liquid assets exceed its short-term obligations, indicating a relatively stable short-term financial position. The company also operates with a moderate level of debt, which could provide some financial flexibility.
The stock's performance has been mixed, with a significant 29.64% price increase over the past six months, but a 21.08% decline in the past week. This volatility aligns with the InvestingPro Tip noting that the stock has taken a big hit over the last week.
For investors seeking a more comprehensive analysis, InvestingPro offers 10 additional tips for Adaptive Biotechnologies, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.